CTRI/2022/04/041817已完成3 期
A Multicenter, Randomized, Open-Label, Parallel-Group, Two-Arm, Phase III, Active Controlled Comparative Study to Assess Efficacy and Safety of Fixed Dose Combination of Dapagliflozin, Sitagliptin and Metformin Hydrochloride Tablets in Comparison to Fixed Dose Combination of Sitagliptin and Metformin Hydrochloride in Patients With Type 2 Diabetes Mellitus
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Patients of either gender, aged 18 to 65 years (both inclusive) and ready to give written informed consent to participate in the study at the time of screening
- •2) Patients with documented diagnosis of type 2 diabetes mellitus
- •3) Patients along with diet and exercise control, and on FDC of Sitagliptin and Metformin (50 mg+500 mg) OR (50 mg + 1000 mg) twice daily (BID) for at least 8 weeks prior to screening
- •4) Patients with Glycated hemoglobin (HbA1c) >=7.5% to <=11% at screening
- •5) Patients with body mass index (BMI) <= 45.0 kg/m2 at screening
- •6) Women of childbearing potential must have a negative urine pregnancy test prior to study entry and agree to use highly effective methods of contraception to prevent pregnancy from study entry till at least two weeks after the last dose of the study medication (such contraception may include hormonal birth control e.g., combined estrogen and progestogen containing [oral, intravaginal, or transdermal] or progesterone only [oral, injectable, or implantable] hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone releasing system OR bilateral tubal occlusion, vasectomized partner, or total sexual abstinence)
- •[Note: Women with childbearing potential are defined as: those who are not (1) surgically sterile (bilateral oophorectomy, hysterectomy, or bilateral tubal ligation) or (2) post-menopausal. Post-menopausal woman will be defined as: Woman not using hormonal replacement therapy and have had at least 12 continuous months of natural (spontaneous) amenorrhea and be greater than 45 years of age.]
排除标准
- •1. Patients with documented diagnosis of type 1 diabetes, diabetes insipidus, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes (e.g. Cushing syndrome or acromegaly- associated diabetes)
- •2. Patients with Fasting Blood Glucose (FBG) >= 270 mg/dL at screening (if required, measurement can be repeated and confirmed within 7 days)
- •3. Patients with history of hypersensitivity to any of the study drug or to drugs of similar chemical classes (e.g. sulfonamide) or to any of its excipients
- •4. Patients with administration of any therapy for diabetes, other than Metformin and Sitagliptin during the 8 weeks prior to screening
- •5. Patients with history of taking any weight loss medications within 3 months prior to randomization
- •6. Patients planning to take any anti-diabetic drugs or weight loss drugs other than study drugs or rescue medication during the study
- •7. Treatment with glucocorticoids equivalent to oral prednisolone >= 10 mg (betamethasone >= 1.2 mg, dexamethasone >= 1.5 mg, hydrocortisone >= 40 mg) per day within 30 days prior to randomization; topical, nasal or inhaled corticosteroids are allowed
- •8. Patients with history of Human immunodeficiency virus (HIV) and/or Hepatitis B virus (HBV) and/ or Hepatitis C virus (HCV)
- •9. Patients having significant renal (estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m2) or hepatic impairment (aspartate transaminase [AST] and alanine transaminase [ALT] Ë? 3 x upper limit of normal [ULN])
- •10. Patients taking loop diuretics within one week prior to screening or planning to take during the study
- •11. Patients suffering with end-stage renal disease or on dialysis
- •12. Any condition (e.g. infection, trauma, surgery) which require insulin therapy at the time of screening or during the study period. Short term use i.e. <= 7 days will be allowed.
- •13. History of bariatric surgery (i.e. any surgery to treat obesity; for example, gastric banding or procedures that involve bypassing or transposing sections of the small intestine). History of liposuction is allowed
- •14. Patients having history of acute or chronic metabolic acidosis, including diabetic ketoacidosis and lactic acidosis, pancreatitis or hyperosmolar state (including coma)
- •15. Patients having history or currently suffering with severe and disabling arthralgia
- •16. Patients who are lactose intolerant
- •17. Patients suffering from severe urinary tract infections (e.g. urosepsis, pyelonephritis), necrotizing fasciitis of the perineum (Fournierâ??s gangrene), intravascular volume contraction and/ or female genital mycotic infections prior to 6 months from screening.
- •18. Patients having history or currently suffering with bullous pemphigoid requiring hospitalization
- •19. Patients with history of myocardial infarction, coronary artery bypass surgery or percutaneous coronary intervention, stroke or transient ischemic attack prior to 6 months from screening
- •20. Patients with history of unstable angina prior to 3 months from screening
- •21. Patients with history of sustained and clinically relevant ventricular arrhythmia
- •22. Any of the following electrocardiogram (ECG) abnormalities:
- •- Second or third degree atrio-ventricular (AV) block without a pacemaker
- •- Long QT syndrome or QTc > 500 ms
- •23. Patients having history or currently sufferi
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Open-Label, Parallel-Group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)The myelodysplastic syndromes (MDS) are a group of potentially acute myeloid leukemic disorders. The disorders of myeloid origin include acute myeloid leukemia (AML), MDS and myeloproliferative disorders such as chronic myeloid leukemia.MedDRA version: 6.1Level: PTClassification code 10028533EUCTR2004-001507-35-HUPharmion Corporation354
进行中（未招募）
1 期
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid ArthritisMedDRA version: 18.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-004339-21-PLsanofi-aventis Recherche & Développement200
进行中（未招募）
不适用
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisEUCTR2009-015556-15-CZBiogen Idec Limited76
进行中（未招募）
不适用
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisEUCTR2009-015556-15-LVBiogen Idec Limited76
进行中（未招募）
1 期
A Multicenter, Randomized, Open-Label, Parallel-Group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)The myelodysplastic syndromes (MDS) are a group of potentially acute myeloid leukemic disorders. The disorders of myeloid origin include acute myeloid leukemia (AML), MDS and myeloproliferative disorders such as chronic myeloid leukemia.MedDRA version: 6.1Level: PTClassification code 10028533EUCTR2004-001507-35-CZPharmion Corporation32